Related Experiment Videos
Intracellular antibody-caspase-mediated cell killing: an approach for application in cancer therapy
1Medical Research Council Laboratory of Molecular Biology, Division of Protein and Nucleic Acid Chemistry, Hills Road, Cambridge CB2 2QH, United Kingdom.
Abstract:
Antibodies have been expressed inside cells in an attempt to ablate the function of oncogene products. To make intracellular antibodies more generally applicable and effective in cancer therapy, we have devised a method in which programmed cell death or apoptosis can be triggered by specific antibody-antigen interaction. When intracellular antibodies are linked to caspase 3, the "executioner" in the apoptosis pathway, and bind to the target antigen, the caspase 3 moieties are self-activated and thereby induce cell killing. We have used this strategy in a model system with two pairs of intracellular antibodies and antigens. In vivo coexpression of an antibody-caspase 3 fusion with its antigenic target induced apoptosis that was specific for antibody, antigen, and active caspase 3. Moreover, the antibody-caspase 3 fusion protein was not toxic to cells in the absence of antigen. Therefore, intracellular antibody-mediated apoptosis should be useful as a specific therapeutic approach for the treatment of cancers, a situation where target cell killing is required.
Insights
Researchers developed a novel cancer therapy using intracellular antibodies fused to caspase 3. This fusion protein triggers targeted cancer cell death (apoptosis) upon binding to specific antigens, offering a promising new treatment strategy.
Area of Science:
- Molecular Biology
- Immunology
- Cancer Research
Background:
- Intracellular antibodies are explored for ablating oncogene function in cancer.
- Current methods for intracellular antibody application in cancer therapy require enhancement for effectiveness.
Purpose of the Study:
- To devise a method for triggering programmed cell death (apoptosis) via specific intracellular antibody-antigen interactions.
- To develop a targeted cancer therapy utilizing antibody-mediated apoptosis.
Main Methods:
- Engineered intracellular antibodies fused to caspase 3, the key executioner protein in apoptosis.
- Coexpression of antibody-caspase 3 fusion proteins with their target antigens in a model system.
- Assessed apoptosis induction specificity and toxicity in the absence of antigen.
Main Results:
- Specific antibody-antigen interaction successfully triggered apoptosis in target cells.
- The antibody-caspase 3 fusion protein demonstrated specificity for antibody, antigen, and active caspase 3.
- The fusion protein showed no toxicity in cells lacking the target antigen.
Conclusions:
- Intracellular antibody-mediated apoptosis is a feasible strategy for targeted cancer cell killing.
- This approach offers a specific and potentially less toxic therapeutic option for cancer treatment.
- The developed method enhances the applicability and effectiveness of intracellular antibodies in cancer therapy.